Beam Therapeutics Growth, Revenue, Number of Employees and Funding
Revenue & Financials
- Beam Therapeutics received $135.0M in venture funding in March 2019. 0
- Beam Therapeutics's total funding is $222M.
- Beam Therapeutics has 66 Employees.
- Beam Therapeutics grew their employee count by 267% last year.
- Beam Therapeutics currently has 13 job openings.
What Is Beam Therapeutics?
Beam Therapeutics is developing precision genetic medicines for serious diseases. Co-founded by scientific pioneers known for advancing CRISPR gene editing, were the first company to pursue development of new therapies using CRISPR base editing technology. We aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. WHO WE ARE Beam is creating precision genetic medicines through base editing WHY WE DO IT Our dream is to provide life-long cures for patients suffering from serious diseases WHO WE ARE AND HOW WE WORK TOGETHER The Beam Team: A community of fearless innovators Rigorous and honest in our research Listening with open minds Committed to each otherkeywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Beam Therapeutics News
Beam Therapeutics made a splash last year when it launched with $87 million to develop medicines that use a more precise form of CRISPR
Cambridge, Massachusetts-based Beam Therapeutics said Wednesday that it had closed a $135 million Series B funding round.
Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, announced the successful
Beam Therapeutics Funding
|2018-05-15||$87.0M||A||F-Prime Capital Partners||Article|